BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that David Stack, President and Chief Executive Officer of Pacira Pharmaceuticals, has joined Amarin's Board of Directors as an independent director effective December 10, 2012.
Mr. Stack has more than 25 years of successful pharmaceutical industry experience. Beyond his current role as President, Chief Executive Officer and Director of Pacira Pharmaceuticals, Mr. Stack is also a Managing Director at MPM Capital, and Founding Partner of Stack Pharmaceuticals, Inc. Mr. Stack's extensive experience includes, from 2001 to 2004, President, CEO and a Director of The Medicines Company where he was recognized as the Ernst and Young Entrepreneur of the Year in 2003. Prior to The Medicines Company, Mr. Stack was the President and General Manager of Innovex Inc., Vice President of Business Development and Marketing for Immunomedics, Inc., and Director of Business Development and Planning for Infectious Disease, Oncology and Virology of Roche Laboratories. Mr. Stack holds a degree in pharmacy from Albany College and a BS in biology from Siena College where he is currently a Trustee. Mr. Stack is a Director of Medivo, Inc. and PepTx, Inc.
"The addition of Dave Stack further expands on the operational experience of the Amarin Board of Directors and enhances the Board's outstanding talent and pharmaceutical industry expertise," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Dave's insights will be valuable as we continue toward the Vascepa commercial launch early in the first quarter of 2013.""Amarin has a unique asset in Vascepa, a great management team and strong momentum as it seeks to lead the next generation of lipid management," stated Mr. Stack. "I look forward to working with Amarin's Board and management team as the company capitalizes on such a significant market opportunity."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV